A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02B
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Merck Sharp & Dohme
Start Date
April 2, 2021
End Date
February 9, 2024
Administered By
Duke Cancer Institute
Awarded By
Merck Sharp & Dohme
Start Date
April 2, 2021
End Date
February 9, 2024